Results 71 to 80 of about 8,448,017 (179)

Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation

ClinicoEconomics and Outcomes Research, 2015
Giovanni Cenderello,1 Stefania Artioli,2 Claudio Viscoli,3 Ambra Pasa,4 Mauro Giacomini,5 Barbara Giannini,5 Chiara Dentone,6 Laura Ambra Nicolini,3 Giovanni Cassola,1 Antonio Di Biagio31Infectious Diseases Unit EO, Ospedali Galliera, Genoa, 2Infectious ...
Cenderello G, Artioli S, Viscoli C, Pasa A, Giacomini M, Giannini B, Dentone C, Nicolini LA, Cassola G, Di Biagio A   +9 more
doaj  

Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis

ClinicoEconomics and Outcomes Research, 2019
Alberto Migliore,1 Davide Integlia,2 Giuseppe Pompilio,2 Francesca Di Giuseppe,2 Cinzia Aru,2 Tray Brown31Unit of Rheumatology, San Pietro Fatebenefratelli Hospital, Rome, Italy; 2ISHEO Srl, Rome, Italy; 3Department of Public Health and Primary Care ...
Migliore A, Integlia D, Pompilio G, Di Giuseppe F, Aru C, Brown T   +5 more
doaj  

Correction: Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]

Front Public Health
Hamida JA, Alkhatib NS, Hammour KA, Halloush S, Kurdi A, Balkhi B, Alfayez OM, Mousa R.   +7 more
europepmc   +2 more sources

Osteoporosis treatment with biosimilars in Malaysia and Thailand: a budget impact analysis. [PDF]

Arch Osteoporos
Siachalinga L, Jones A, Kim K, Downes M, Solev I, Lee K, Valleenukul T, Kim H.   +7 more
europepmc   +1 more source

Cost-effectiveness and budget impact analyses of strategies to improve measles vaccination coverage in Kenya. [PDF]

PLOS Glob Public Health
Orangi S, Mandaliya P, Jalang'o R, Amoth P, Banda A, Anosike C, Masiye F, Onwujekwe O, Barasa E.   +8 more
europepmc   +1 more source

Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model. [PDF]

Pharmacoecon Open
Porta C, Di Procolo P, Marrazzo G, Belfiore M, Palladino R, Brescia Morra V, Moccia M.   +6 more
europepmc   +1 more source

Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]

Front Public Health
Hamida JA, Alkhatib NS, Hammour KA, Halloush S, Kurdi A, Balkhi B, Alfayez OM, Mousa R.   +7 more
europepmc   +1 more source

Budget impact analysis of medication reviews by junior pharmacists in polypharmacy patients: a hospital perspective. [PDF]

Int J Clin Pharm
Hectors T, Kooijman T, van Barreveld M, Kuijvenhoven M, Teeuwisse P, Olde Engberink R.   +5 more
europepmc   +1 more source

TACE combined with apatinib versus TACE alone for unresectable hepatocellular carcinoma in China: a cost-effectiveness and budget impact analysis. [PDF]

BMJ Open
Zhang Y, Wang X, Huang Z, Huang L, Sun G.   +4 more
europepmc   +1 more source

Economic impact of initiation of home mechanical ventilation: a budget impact analysis from the Netherlands. [PDF]

BMJ Open Respir Res
van den Biggelaar R, Duiverman M, Hazenberg A, van Boven JFM, Vermeulen K, Wijkstra PJ.   +5 more
europepmc   +1 more source